macrocycl
peptid
privileg
scaffold
drug
develop
constitut
signific
portion
macrocycl
drug
market
today
field
span
infecti
diseas
oncolog
develop
oral
bioavail
peptidebas
drug
remain
challeng
task
howev
macrocycl
linear
peptid
effect
strategi
improv
membran
permeabl
proteolyt
stabil
oral
bioavail
overal
druglik
characterist
class
signific
advanc
solidphas
peptid
synthesi
spp
enabl
effici
construct
macrocycl
peptid
peptidomimet
librari
macrolactam
perform
onresin
solut
phase
primari
goal
review
summar
solidphas
cyclohexapeptid
synthesi
use
onresin
solutionphas
macrocycl
methodolog
publish
sinc
also
highlight
broad
applic
rang
natur
product
total
synthesi
synthet
methodolog
develop
medicin
chemistri
drug
develop
analys
conform
physiochem
properti
molecul
incorpor
peptid
sequenc
precycl
pseudoprolin
residu
deprotect
post
cycliz
coupl
reagent
azabenzotriazol
class
commonli
employ
cycliz
linear
peptid
precursor
give
faster
rate
cycliz
lower
amount
epimer
typic
less
moreov
linear
peptid
dconfigur
ctermin
residu
favor
cycliz
kinet
may
result
less
steric
hindranc
format
peptid
bond
occur
dand
lamino
acid
particularli
bulki
side
chain
present
cyclodepsipeptid
one
ester
linkag
macrocycl
backbon
util
epimerizationfre
synthesi
cyclopeptid
employ
key
onacyl
migrat
reaction
serin
residu
macrocycl
peptid
known
possess
improv
membran
permeabl
proteolyt
stabil
oral
bioavail
overal
druglik
characterist
linear
analogu
moreov
peptid
macrocycl
way
lock
peptid
sequenc
conform
conform
often
recogn
enzym
target
proteas
macrocycl
complet
rigid
still
degre
flexibl
facilit
interact
receptor
addit
entrop
cost
receptor
bind
may
reduc
macrocycl
drug
compar
linear
equival
result
conform
preorgan
nmethyl
cyclic
peptid
backbon
shown
case
improv
peptid
metabol
stabil
oral
bioavail
result
chang
peptid
conform
steric
hindranc
immunosuppress
drug
ciclosporin
macrocycl
undecapeptid
bear
seven
nmethyl
motif
administ
oral
formul
modif
cyclohexapeptid
backbon
form
cyclohexapeptoid
case
lead
increas
cell
permeabl
cyclic
peptid
drug
market
today
administ
parenter
oral
bioavail
highlight
ongo
challeng
reason
synthesi
evalu
novel
cyclopeptid
scaffold
expand
understand
pharmacokinet
pk
properti
still
forefront
mani
research
program
solidphas
peptid
synthesi
spp
first
describ
merrifield
wherebi
grow
linear
peptid
synthes
stepwis
fashion
coval
attach
solid
support
resin
gener
excess
reagent
use
solidphas
synthesi
help
drive
reaction
complet
solidsupport
methodolog
allow
excess
reagent
remov
step
employ
simpl
filtrat
final
desir
product
obtain
cleavag
resin
date
mani
new
advanc
spp
allow
rapid
effici
construct
peptid
peptidomimet
librari
subsequ
biolog
evalu
highthroughput
screen
current
literatur
base
surround
natur
synthet
macrocycl
peptid
extens
structur
macrocycl
widerang
incorpor
natur
unnatur
amino
acid
well
differ
ring
size
interestingli
cyclohexapeptidesmacrocycl
peptid
compris
six
amino
acid
ringar
one
ubiquit
class
macrocycl
peptid
synthes
spp
macrocycl
hexapeptid
obtain
directli
onresin
solutionphas
cycliz
follow
cleavag
linear
hexapeptid
precursor
resin
figur
brief
review
summar
preced
five
year
worth
solidphas
cyclohexapeptid
synthesi
applic
span
natur
product
total
synthesi
synthet
methodolog
develop
medicin
chemistri
drug
develop
analys
conform
physiochem
properti
macrocycl
peptid
constitut
signific
portion
macrocycl
drug
market
today
use
mani
field
rang
infecti
diseas
oncolog
recent
report
antibacteri
macrocycl
peptid
natur
product
demonstr
macrocycl
peptid
privileg
scaffold
drug
develop
histor
pharmaceut
industri
cautiou
develop
macrocycl
drug
concern
higher
cost
synthet
challeng
associ
lead
optim
scaleup
campaign
headtotail
cycliz
linear
peptid
three
eight
amino
acid
challeng
particularli
peptid
contain
exclus
lconfigur
format
linear
well
cyclic
dimer
oligom
cycliz
step
compet
headtotail
cycliz
addit
epimer
ctermin
amino
acid
commonli
encount
ctermin
activ
step
cycliz
reaction
take
place
date
signific
progress
made
synthesi
macrocycl
make
effici
construct
feasibl
common
strategi
improv
headtotail
cycliz
small
peptid
involv
incorpor
turninduc
function
linear
peptid
sequenc
glycin
prolin
pseudoprolin
nalkyl
damino
acid
residu
case
pseudoprolin
method
pseudoprolin
residu
synthes
condens
serin
threonin
cystein
aldehyd
keton
wu
et
al
report
structur
two
new
cyclohexapeptid
nocardiamid
b
isol
cultur
broth
strain
actinomycet
nocardiopsi
speci
figur
structur
confirm
independ
total
synthesi
help
confirm
locat
two
dand
lval
residu
synthesi
shown
scheme
synthesi
use
chlorid
resin
solid
support
construct
linear
hexapeptid
use
classic
spp
follow
cleavag
resin
use
trifluoroacet
wu
et
al
report
structur
two
new
cyclohexapeptid
nocardiamid
b
isol
cultur
broth
strain
actinomycet
nocardiopsi
speci
figur
wu
et
al
report
structur
two
new
cyclohexapeptid
nocardiamid
b
isol
cultur
broth
strain
actinomycet
nocardiopsi
speci
figur
structur
confirm
independ
total
synthesi
help
confirm
locat
two
dand
lval
residu
synthesi
shown
scheme
synthesi
use
chlorid
resin
solid
support
construct
linear
hexapeptid
use
classic
spp
follow
cleavag
resin
use
trifluoroacet
work
solidsupport
linear
hexapeptid
prepar
resin
standard
microwaveassist
fmoc
spp
scheme
cleavag
hexapeptid
resin
done
use
tfa
afford
unprotect
linear
peptid
yield
subsequ
cycliz
use
tripyrrolidinophosphonium
hexafluorophosph
pybop
dimethylformamid
dmf
gave
cyclohexapeptid
quantit
yield
h
interestingli
cycliz
proceed
much
faster
correspond
otertbutyl
protect
linear
peptid
counterpart
cyclic
hexapeptid
use
produc
new
class
cyclohexapeptidecontain
hemicryptophan
investig
enantioselect
bind
properti
complex
carnitin
work
solidsupport
linear
hexapeptid
prepar
resin
standard
microwaveassist
fmoc
spp
scheme
cleavag
hexapeptid
resin
done
use
tfa
ch
cnh
afford
unprotect
linear
peptid
yield
subsequ
cycliz
use
tripyrrolidinophosphonium
hexafluorophosph
pybop
dimethylformamid
dmf
gave
cyclohexapeptid
quantit
yield
h
interestingli
cycliz
proceed
much
faster
correspond
otertbutyl
protect
linear
peptid
counterpart
cyclic
hexapeptid
use
produc
new
class
cyclohexapeptidecontain
hemicryptophan
investig
enantioselect
bind
properti
complex
carnitin
peptidebas
therapeut
notori
poor
oral
bioavail
profil
low
plasma
stabil
limit
use
oral
deliv
drug
although
nmethyl
cyclohexapeptid
shown
improv
oral
bioavail
hill
et
al
demonstr
cyclohexaleucin
peptid
without
nmethyl
function
show
degre
oral
bioavail
respect
interestingli
epim
show
lower
oral
bioavail
result
notabl
higher
plasma
clearanc
rate
versu
mlminkg
reason
suggest
caus
differ
solvent
exposur
peptid
backbon
result
conform
chang
leu
residu
membran
permeabl
measur
use
rrck
cell
monolay
former
lack
activ
transport
rrck
assay
compound
show
greater
membran
permeabl
control
standard
cyclosporin
csa
assay
show
similar
permeabl
csa
papp
shown
scheme
cyclohexaleucin
peptid
synthes
use
spp
resin
linear
hexapeptid
precursor
follow
cleavag
resin
solutionphas
cycliz
dilut
condit
epim
form
final
cycliz
step
could
success
separ
purif
use
reversephas
highperform
liquid
chromatographi
rphplc
observ
epimer
due
wellknown
epimer
process
take
place
carboxyl
acid
activ
step
prior
cycliz
exampl
epim
ratio
peptidebas
therapeut
notori
poor
oral
bioavail
profil
low
plasma
stabil
limit
use
oral
deliv
drug
although
nmethyl
cyclohexapeptid
shown
improv
oral
bioavail
hill
et
al
demonstr
cyclohexaleucin
peptid
without
nmethyl
function
show
degre
oral
bioavail
respect
interestingli
epim
lower
oral
bioavail
result
notabl
higher
plasma
clearanc
rate
versu
mlminkg
reason
suggest
caus
differ
solvent
exposur
peptid
backbon
result
conform
chang
leu
residu
membran
permeabl
measur
use
rrck
cell
monolay
former
lack
activ
transport
rrck
assay
compound
show
greater
membran
permeabl
control
standard
cyclosporin
csa
assay
show
similar
permeabl
csa
p
app
shown
scheme
cyclohexaleucin
peptid
synthes
use
spp
resin
linear
hexapeptid
precursor
follow
cleavag
resin
solutionphas
cycliz
dilut
condit
epim
form
final
cycliz
step
could
success
separ
purif
use
reversephas
highperform
liquid
chromatographi
rphplc
observ
epimer
due
wellknown
epimer
process
take
place
carboxyl
acid
activ
step
prior
cycliz
exampl
epim
ratio
masuda
et
al
report
total
synthesi
insecticid
activ
cyclohexapeptid
natur
product
c
f
g
figur
produc
organ
commonli
fungi
hamigera
avellanea
acremonium
penicillium
speci
particular
interest
high
degre
damino
acid
incorpor
dala
daba
dalloil
dval
within
macrocycl
scaffold
natur
product
also
contain
nonproteinogen
anthranil
acid
ant
lpipecolin
acid
pip
residu
suggest
nonribosom
biosynthet
pathway
may
use
produc
organ
enhanc
bioavail
natur
product
attribut
improv
cell
permeabl
via
passiv
diffus
higher
metabol
stabil
due
cyclic
natur
incorpor
damino
acid
synthesi
achiev
via
initi
construct
linear
hexapeptid
spp
use
trityl
alcohol
synphas
lantern
solid
support
repres
synthesi
construct
cyclohexapeptid
shown
scheme
spp
start
attach
fmocdalaoh
fmocdabaoh
allow
final
solutionphas
hbtumedi
macrocycl
step
proceed
least
amount
steric
hindranc
nmethylleu
lpipecolin
acid
anthranil
acid
function
seen
incorpor
peptid
sequenc
employ
fmoclmeleuoh
fmoclpipoh
fmocantoh
spp
respect
coupl
weakli
nucleophil
amino
function
ntermin
anthranil
acid
residu
fmocamino
acid
chlorid
dalloil
dval
gener
situ
use
triphosgen
prior
coupl
linear
hexapeptid
cleav
resin
use
hexafluoroisopropanol
hfip
dichloromethan
dcm
cycliz
solut
use
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
hatu
n
ndiisopropylethylamin
dipea
dcm
room
temperatur
h
afford
natur
product
test
fourthinstar
larva
assay
found
paralyt
activ
silkworm
larva
stereochemistri
dala
side
chain
found
crucial
paralyt
activ
sidechain
epim
lala
place
dala
show
littl
activ
masuda
et
al
report
total
synthesi
insecticid
activ
cyclohexapeptid
natur
product
c
f
g
figur
produc
organ
commonli
fungi
hamigera
avellanea
acremonium
penicillium
speci
particular
interest
high
degre
damino
acid
incorpor
dala
daba
dalloil
dval
within
macrocycl
scaffold
natur
product
also
contain
nonproteinogen
anthranil
acid
ant
lpipecolin
acid
pip
residu
suggest
nonribosom
biosynthet
pathway
may
use
produc
organ
enhanc
bioavail
natur
product
attribut
improv
cell
permeabl
via
passiv
diffus
higher
metabol
stabil
due
cyclic
natur
incorpor
damino
acid
synthesi
achiev
via
initi
construct
linear
hexapeptid
spp
use
trityl
alcohol
synphas
lantern
solid
support
repres
synthesi
construct
cyclohexapeptid
shown
scheme
spp
start
attach
fmocdalaoh
fmocdabaoh
allow
final
solutionphas
hbtumedi
macrocycl
step
proceed
least
amount
steric
hindranc
nmethylleu
lpipecolin
acid
anthranil
acid
function
seen
incorpor
peptid
sequenc
employ
fmoclmeleuoh
fmoclpipoh
fmocantoh
spp
respect
coupl
weakli
nucleophil
amino
function
ntermin
anthranil
acid
residu
fmocamino
acid
chlorid
dalloil
dval
gener
situ
use
triphosgen
prior
coupl
linear
hexapeptid
cleav
resin
use
hexafluoroisopropanol
hfip
dichloromethan
dcm
cycliz
solut
use
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
hatu
n
ndiisopropylethylamin
dipea
dcm
room
temperatur
h
afford
natur
product
test
fourthinstar
larva
assay
found
paralyt
activ
silkworm
larva
stereochemistri
dala
side
chain
found
crucial
paralyt
activ
sidechain
epim
lala
place
dala
show
littl
activ
et
al
report
synthesi
antimalari
antitrypanosom
activ
seven
novel
cyclohexapeptid
incorpor
interest
thiazol
function
studi
prompt
earlier
report
cyanobacterium
microcysti
aeruginosa
pcc
natur
product
aerucyclamid
ad
figur
display
promis
micromolar
maxim
inhibitori
concentr
valu
chloroquineresist
strain
plasmodium
falciparum
spp
linear
hexapeptid
precursor
conduct
use
resin
standard
fmoc
chemistri
scheme
first
fmocamino
acid
load
onto
resin
dcm
presenc
dipea
follow
cap
unreact
resin
site
methanol
synthesi
resin
first
load
fmocprotect
thiazol
residu
fmocthzoh
use
analog
condit
subsequ
amino
acid
instal
via
iter
deprotect
piperidin
dmf
coupl
n
ndiisopropylcarbodiimid
dic
pyridin
hoat
dmf
step
cleavag
linear
hexapeptid
resin
use
tfa
dcm
macrocycl
perform
use
hbtu
dipea
catalyt
dmap
dcm
dilut
condit
mm
coupl
site
macrocycl
chosen
occur
ntermin
glycin
ctermin
glycin
ctermin
thiazol
provid
least
degre
steric
hindranc
result
favor
yield
moreov
cycliz
linear
precursor
afford
took
place
ctermin
glycin
thiazol
prevent
epimer
et
al
report
synthesi
antimalari
antitrypanosom
activ
seven
novel
cyclohexapeptid
incorpor
interest
thiazol
function
studi
prompt
earlier
report
cyanobacterium
microcysti
aeruginosa
pcc
natur
product
aerucyclamid
ad
figur
display
promis
micromolar
maxim
inhibitori
concentr
valu
chloroquineresist
strain
plasmodium
falciparum
spp
linear
hexapeptid
precursor
conduct
use
resin
standard
fmoc
chemistri
scheme
first
fmocamino
acid
load
onto
resin
dcm
presenc
dipea
follow
cap
unreact
resin
site
methanol
synthesi
resin
first
load
fmocprotect
thiazol
residu
fmocthzoh
use
analog
condit
subsequ
amino
acid
instal
via
iter
deprotect
piperidin
dmf
coupl
n
ndiisopropylcarbodiimid
dic
pyridin
hoat
dmf
step
cleavag
linear
hexapeptid
resin
use
tfa
dcm
macrocycl
perform
use
hbtu
dipea
catalyt
dmap
dcm
dilut
condit
mm
coupl
site
macrocycl
chosen
occur
ntermin
glycin
ctermin
glycin
ctermin
thiazol
provid
least
degre
steric
hindranc
result
favor
yield
moreov
cycliz
linear
precursor
afford
took
place
ctermin
glycin
thiazol
prevent
epimer
studi
prompt
earlier
report
cyanobacterium
microcysti
aeruginosa
pcc
natur
product
aerucyclamid
ad
figur
display
promis
micromolar
ic
maxim
inhibitori
concentr
valu
chloroquineresist
strain
plasmodium
falciparum
spp
linear
hexapeptid
precursor
conduct
use
resin
standard
fmoc
chemistri
scheme
first
fmocamino
acid
load
onto
resin
dcm
presenc
dipea
follow
cap
unreact
resin
site
methanol
synthesi
resin
first
load
fmocprotect
thiazol
residu
fmocthzoh
use
analog
condit
subsequ
amino
acid
instal
via
iter
deprotect
piperidin
dmf
coupl
n
ndiisopropylcarbodiimid
dic
pyridin
hoat
dmf
step
cleavag
linear
hexapeptid
resin
use
tfa
dcm
macrocycl
perform
use
hbtu
dipea
catalyt
dmap
dcm
dilut
condit
mm
coupl
site
macrocycl
chosen
occur
ntermin
glycin
ctermin
glycin
ctermin
thiazol
provid
least
degre
steric
hindranc
result
favor
yield
moreov
cycliz
linear
precursor
afford
took
place
ctermin
glycin
thiazol
prevent
epimer
cyclohexapeptid
screen
p
falciparum
infect
b
brucei
assay
particular
interest
promis
antimalari
activ
shown
p
falciparum
maxim
effect
concentr
valu
respect
observ
cell
cytotox
murin
macrophag
also
noteworthi
antitrypanosom
activ
b
brucei
valu
respect
wong
et
al
report
total
synthesi
dichotomin
figur
linear
peptid
precursor
contain
penicillaminederiv
pseudoprolin
residu
scheme
util
pseudoprolin
residu
place
proteinogen
val
residu
synthesi
dichotomin
protect
group
stratergi
way
improv
headtotail
cycliz
linear
peptid
precursor
abil
pseudoprolin
induc
turn
kink
peptid
backbon
well
aid
peptid
solubl
pseudoprolin
residu
deprotect
convert
desir
val
residu
post
cycliz
afford
dichotomin
cyclohexapeptid
screen
p
falciparum
infect
b
brucei
assay
particular
interest
promis
antimalari
activ
shown
p
falciparum
maxim
effect
concentr
valu
respect
observ
cell
cytotox
murin
macrophag
also
noteworthi
antitrypanosom
activ
b
brucei
valu
respect
wong
et
al
report
total
synthesi
dichotomin
figur
linear
peptid
precursor
contain
penicillaminederiv
pseudoprolin
residu
scheme
util
pseudoprolin
residu
place
proteinogen
val
residu
synthesi
dichotomin
protect
group
stratergi
way
improv
headtotail
cycliz
linear
peptid
precursor
abil
pseudoprolin
induc
turn
kink
peptid
backbon
well
aid
peptid
solubl
pseudoprolin
residu
deprotect
convert
desir
val
residu
post
cycliz
afford
dichotomin
cyclohexapeptid
screen
p
falciparum
infect
b
brucei
assay
particular
interest
promis
antimalari
activ
shown
p
falciparum
ec
maxim
effect
concentr
valu
respect
observ
cell
cytotox
murin
macrophag
also
noteworthi
antitrypanosom
activ
b
brucei
ec
valu
respect
wong
et
al
report
total
synthesi
dichotomin
figur
linear
peptid
precursor
contain
penicillaminederiv
pseudoprolin
residu
scheme
util
pseudoprolin
residu
place
proteinogen
val
residu
synthesi
dichotomin
protect
group
stratergi
way
improv
headtotail
cycliz
linear
peptid
precursor
abil
pseudoprolin
induc
turn
kink
peptid
backbon
well
aid
peptid
solubl
pseudoprolin
residu
deprotect
convert
desir
val
residu
post
cycliz
afford
dichotomin
dichotomin
prepar
two
differ
disconnect
site
within
macrocycl
ring
scheme
first
linear
peptid
precursor
contain
nonepimeriz
ctermin
glycin
ntermin
otertbutyl
protect
threonin
residu
second
peptid
precursor
contain
epimeriz
ntermin
leucin
ctermin
phenylalanin
creat
steric
hinder
cycliz
site
provid
way
test
robust
methodolog
linear
peptid
contain
pseudoprolin
residu
synthes
resin
use
standard
fmocstrategi
spp
hbtu
coupl
reagent
piperidin
dmf
fmoc
deprotect
cleavag
resin
done
use
hfip
dcm
keep
sidechain
protect
group
intact
conform
establish
use
h
nuclear
magnet
reson
nmr
spectroscopi
rotatingfram
overhaus
effect
spectroscopi
roesi
experi
also
confirm
singl
set
reson
structur
peptid
macrocycl
obtain
linear
peptid
contain
pseudoprolin
residu
less
h
good
excel
yield
use
tetrafluorobor
contrast
cycliz
analog
linear
peptid
precursor
contain
nativ
val
residu
much
slower
reaction
kinet
requir
day
reaction
complet
lower
yield
pseudoprolin
otertbutylthr
residu
simultan
deprotect
use
trifluoromethanesulfon
acid
tfmsa
water
vv
give
follow
desulfur
use
nicl
nabh
meoh
afford
dichotomin
yield
molecul
x
peer
review
dichotomin
prepar
two
differ
disconnect
site
within
macrocycl
ring
scheme
first
linear
peptid
precursor
contain
nonepimeriz
ctermin
glycin
ntermin
otertbutyl
protect
threonin
residu
second
peptid
precursor
contain
epimeriz
ntermin
leucin
ctermin
phenylalanin
creat
steric
hinder
cycliz
site
provid
way
test
robust
methodolog
linear
peptid
contain
pseudoprolin
residu
synthes
resin
use
standard
fmocstrategi
spp
hbtu
coupl
reagent
piperidin
dmf
fmoc
deprotect
cleavag
resin
done
use
hfip
dcm
keep
sidechain
protect
group
intact
conform
establish
use
h
nuclear
magnet
reson
nmr
spectroscopi
rotatingfram
overhaus
effect
spectroscopi
roesi
experi
also
confirm
singl
set
reson
structur
peptid
macrocycl
obtain
linear
peptid
contain
pseudoprolin
residu
less
h
good
excel
yield
use
tetrafluorobor
contrast
cycliz
analog
linear
peptid
precursor
contain
nativ
val
residu
much
slower
reaction
kinet
requir
day
reaction
complet
lower
yield
pseudoprolin
otertbutylthr
residu
simultan
deprotect
use
trifluoromethanesulfon
acid
tfmsa
water
vv
give
follow
desulfur
use
meoh
afford
dichotomin
yield
dichotomin
prepar
two
differ
disconnect
site
within
macrocycl
ring
scheme
first
linear
peptid
precursor
contain
nonepimeriz
ctermin
glycin
ntermin
otertbutyl
protect
threonin
residu
second
peptid
precursor
contain
epimeriz
ntermin
leucin
ctermin
phenylalanin
creat
steric
hinder
cycliz
site
provid
way
test
robust
methodolog
linear
peptid
contain
pseudoprolin
residu
synthes
resin
use
standard
fmocstrategi
spp
hbtu
coupl
reagent
piperidin
dmf
fmoc
deprotect
cleavag
resin
done
use
hfip
dcm
keep
sidechain
protect
group
intact
conform
establish
use
h
nuclear
magnet
reson
nmr
spectroscopi
rotatingfram
overhaus
effect
spectroscopi
roesi
experi
also
confirm
singl
set
reson
structur
peptid
macrocycl
obtain
linear
peptid
contain
pseudoprolin
residu
less
h
good
excel
yield
use
tetrafluorobor
contrast
cycliz
analog
linear
peptid
precursor
contain
nativ
val
residu
much
slower
reaction
kinet
requir
day
reaction
complet
lower
yield
pseudoprolin
otertbutylthr
residu
simultan
deprotect
use
trifluoromethanesulfon
acid
tfmsa
water
vv
give
follow
desulfur
use
meoh
afford
dichotomin
yield
notic
discrep
compar
h
cnmr
data
synthes
similanamid
report
data
report
data
similanamid
howev
agre
favor
previous
synthes
diastereom
led
structur
revis
similanamid
structur
similar
diastereom
notic
discrep
compar
h
cnmr
data
synthes
similanamid
report
data
report
data
similanamid
howev
agre
favor
previous
synthes
diastereom
led
structur
revis
similanamid
structur
similar
diastereom
amso
et
al
report
synthesi
cyclohexapeptid
dianthin
g
cycloproleuthrleuphegli
well
nine
analogu
includ
n
methyl
deriv
conform
constrain
cyclic
dicarba
bridg
analogu
eg
figur
vitro
osteoblast
prolifer
activ
synthes
compound
determin
dianthin
g
n
methyl
deriv
synthes
spp
follow
cleavag
solutionphas
headtotail
macrolactam
spp
nativ
cyclohexapeptid
dianthin
g
report
previous
later
adapt
synthesi
methyl
analogu
scheme
n
methyl
deriv
amso
et
al
report
synthesi
cyclohexapeptid
dianthin
g
cycloproleuthrleuphegli
well
nine
analogu
includ
n
methyl
deriv
conform
constrain
cyclic
dicarba
bridg
analogu
eg
figur
vitro
osteoblast
prolifer
activ
synthes
compound
determin
dianthin
g
n
methyl
deriv
synthes
spp
follow
cleavag
solutionphas
headtotail
macrolactam
notic
discrep
compar
h
cnmr
data
synthes
similanamid
report
data
report
data
similanamid
howev
agre
favor
previous
synthes
diastereom
led
structur
revis
similanamid
structur
similar
diastereom
amso
et
al
report
synthesi
cyclohexapeptid
dianthin
g
cycloproleuthrleuphegli
well
nine
analogu
includ
n
methyl
deriv
conform
constrain
cyclic
dicarba
bridg
analogu
eg
figur
vitro
osteoblast
prolifer
activ
synthes
compound
determin
dianthin
g
n
methyl
deriv
synthes
spp
follow
cleavag
solutionphas
headtotail
macrolactam
spp
nativ
cyclohexapeptid
dianthin
g
report
previous
later
adapt
synthesi
methyl
analogu
scheme
n
methyl
deriv
spp
nativ
cyclohexapeptid
dianthin
g
report
previous
later
adapt
synthesi
methyl
analogu
scheme
n
methyl
deriv
synthes
aminomethyl
polystyren
resin
propion
acid
hmpp
linker
howev
synthesi
requir
use
hinder
resin
prevent
format
undesir
diketopiperazin
byproduct
repres
synthesi
cyclohexapeptid
shown
scheme
aminomethyl
polystyren
resin
first
load
fmocglyhmppoh
form
solidsupport
linear
pentapeptid
construct
onresin
use
classic
spp
termin
amino
function
activ
react
chlorid
form
follow
methyl
deprotect
afford
attach
final
prolin
residu
hexapeptid
cleav
resin
form
cycliz
use
hbtumedi
solutionphas
cycliz
afford
cyclic
dicarba
analogu
contain
nonn
dicarba
bridg
exampl
synthes
onresin
grubb
ringclos
metathesi
rcm
cleav
resin
form
insepar
mixtur
ci
tran
isom
n
methyl
amid
bond
scan
synthes
dianthin
g
done
investig
effect
alter
amid
bond
osteoblast
prolifer
found
nativ
peptid
bond
contain
primari
sequenc
dianthin
g
import
osteoblast
prolifer
activ
vitro
studi
nativ
dianthin
g
dicarba
bridg
analogu
found
increas
number
human
osteoblast
without
signific
effect
osteoclast
differenti
develop
insepar
ze
mixtur
olefin
ratio
secondari
structur
similar
nativ
dianthin
g
determin
spectroscop
analysi
dicarba
analogu
suggest
secondari
structur
import
bone
activ
associ
dianthin
peptid
synthes
aminomethyl
polystyren
resin
propion
acid
hmpp
linker
howev
synthesi
requir
use
hinder
resin
prevent
format
undesir
diketopiperazin
byproduct
repres
synthesi
cyclohexapeptid
shown
scheme
aminomethyl
polystyren
resin
first
load
fmocglyhmppoh
form
solidsupport
linear
pentapeptid
construct
onresin
use
classic
spp
termin
amino
function
activ
react
chlorid
form
follow
methyl
deprotect
afford
attach
final
prolin
residu
hexapeptid
cleav
resin
form
cycliz
use
hbtumedi
solutionphas
cycliz
afford
cyclic
dicarba
analogu
contain
nonn
dicarba
bridg
exampl
synthes
onresin
grubb
ringclos
metathesi
rcm
cleav
resin
form
insepar
mixtur
ci
tran
isom
n
methyl
amid
bond
scan
synthes
dianthin
g
done
investig
effect
alter
amid
bond
osteoblast
prolifer
found
nativ
peptid
bond
contain
primari
sequenc
dianthin
g
import
osteoblast
prolifer
activ
vitro
studi
nativ
dianthin
g
dicarba
bridg
analogu
found
increas
number
human
osteoblast
without
signific
effect
osteoclast
differenti
develop
insepar
ze
mixtur
olefin
ratio
secondari
structur
similar
nativ
dianthin
g
determin
spectroscop
analysi
dicarba
analogu
suggest
secondari
structur
import
bone
activ
associ
dianthin
peptid
asfaw
et
al
report
synthesi
cyclohexapeptid
wollamid
b
analogu
fmocbas
spp
linear
hexapeptid
precursor
follow
solutionphas
macrocycl
cleavag
protect
group
describ
scheme
first
amino
acid
fmocleuoh
load
onto
resin
use
dipeadcm
follow
cap
methanol
hatu
dipea
nmp
use
coupl
step
elong
peptid
ntermin
fmoc
group
deprotect
round
coupl
use
piperidin
dmf
resin
treat
hfip
dcm
complet
cleavag
linear
hexapeptid
asfaw
et
al
report
synthesi
cyclohexapeptid
wollamid
b
analogu
fmocbas
spp
linear
hexapeptid
precursor
follow
solutionphas
macrocycl
cleavag
protect
group
describ
scheme
first
amino
acid
fmocleuoh
load
onto
resin
use
dipeadcm
follow
cap
methanol
hatu
dipea
nmp
use
coupl
step
elong
peptid
ntermin
fmoc
group
deprotect
round
coupl
use
piperidin
dmf
resin
treat
hfip
dcm
complet
cleavag
linear
hexapeptid
precursor
macrocycl
done
use
hatu
hydroxybenzotriazol
hobt
dipea
dmf
produc
crude
cyclic
hexapeptid
purifi
via
column
chromatographi
lastli
trt
boc
sidechain
protect
group
remov
use
tfatriisopropylsilan
precursor
macrocycl
done
use
hatu
hydroxybenzotriazol
hobt
dipea
dmf
produc
crude
cyclic
hexapeptid
purifi
via
column
chromatographi
lastli
trt
boc
sidechain
protect
group
remov
use
tfatriisopropylsilan
tip
solut
afford
wollamid
b
yield
purif
silica
gel
chromatographi
antimycobacteri
activ
well
vitro
drug
metabol
pk
absorpt
distribut
metabol
excretionadm
profil
structur
analogu
investig
wollamid
b
found
notabl
aqueou
solubl
moder
affin
plasma
protein
albumin
modest
lipophil
poor
passiv
permeabl
artifici
membran
signific
vitro
plasma
stabil
high
microsom
metabol
stabil
toxic
cell
concentr
notabl
five
synthes
wollamid
b
analogu
figur
display
potent
antimycobacteri
activ
minimum
inhibitori
concentr
mic
toxic
cell
concentr
compound
also
show
optim
balanc
antimycobacteri
activ
pk
properti
overal
synthes
wollamid
display
notabl
plasma
stabil
aqueou
solubl
moder
low
metabol
stabil
group
report
total
synthesi
natur
product
wollamid
b
desotamid
b
figur
use
spp
linear
hexapeptid
precursor
follow
cleavag
solutionphas
cycliz
repres
synthesi
use
access
antimycobacteri
activ
well
vitro
drug
metabol
pk
absorpt
distribut
metabol
excretionadm
profil
structur
analogu
investig
wollamid
b
found
notabl
aqueou
solubl
moder
affin
plasma
protein
albumin
modest
lipophil
poor
passiv
permeabl
artifici
membran
signific
vitro
plasma
stabil
high
microsom
metabol
stabil
toxic
cell
concentr
notabl
five
synthes
wollamid
b
analogu
figur
display
potent
antimycobacteri
activ
minimum
inhibitori
concentr
mic
toxic
cell
concentr
compound
also
show
optim
balanc
antimycobacteri
activ
pk
properti
overal
synthes
wollamid
display
notabl
plasma
stabil
aqueou
solubl
moder
low
metabol
stabil
precursor
macrocycl
done
use
hatu
hydroxybenzotriazol
hobt
dipea
dmf
produc
crude
cyclic
hexapeptid
purifi
via
column
chromatographi
lastli
trt
boc
sidechain
protect
group
remov
use
tfatriisopropylsilan
tip
solut
afford
wollamid
b
yield
purif
silica
gel
chromatographi
antimycobacteri
activ
well
vitro
drug
metabol
pk
absorpt
distribut
metabol
excretionadm
profil
structur
analogu
investig
wollamid
b
found
notabl
aqueou
solubl
moder
affin
plasma
protein
albumin
modest
lipophil
poor
passiv
permeabl
artifici
membran
signific
vitro
plasma
stabil
high
microsom
metabol
stabil
toxic
cell
concentr
notabl
five
synthes
wollamid
b
analogu
figur
display
potent
antimycobacteri
activ
minimum
inhibitori
concentr
mic
toxic
cell
concentr
compound
also
show
optim
balanc
antimycobacteri
activ
pk
properti
overal
synthes
wollamid
display
notabl
plasma
stabil
aqueou
solubl
moder
low
metabol
stabil
group
report
total
synthesi
natur
product
wollamid
b
desotamid
b
figur
use
spp
linear
hexapeptid
precursor
follow
cleavag
solutionphas
cycliz
repres
synthesi
use
access
group
report
total
synthesi
natur
product
wollamid
b
desotamid
b
figur
use
spp
linear
hexapeptid
precursor
follow
cleavag
solutionphas
cycliz
repres
synthesi
use
access
wollamid
b
highlight
scheme
first
fmoc
amino
acid
fmocasn
trt
oh
load
onto
resin
aid
dipea
dcm
hexapeptid
sequenc
correspond
wollamid
b
dorntrpleudleuvalasn
synthes
onresin
via
repeat
coupl
deprotect
step
shown
scheme
cleavag
linear
hexapeptid
resin
use
mild
cleavag
reagent
hfip
result
sidechain
residu
protect
group
still
attach
solutionphas
macrocycl
done
use
hbtu
dipea
dmf
provid
protect
cyclohexapeptid
wollamid
b
obtain
remov
sidechain
protect
group
final
purif
use
flash
column
chromatographi
silica
gel
optim
studi
investig
effici
macrocycl
step
occur
six
peptid
bond
site
determin
macrocycl
linear
hexapeptid
precursor
termin
lleu
dleu
residu
provid
effici
macrocycl
without
detect
epimer
wollamid
b
highlight
scheme
first
fmoc
amino
acid
fmocasn
trt
oh
load
onto
resin
aid
dipea
dcm
hexapeptid
sequenc
correspond
wollamid
b
dorntrpleudleuvalasn
synthes
onresin
via
repeat
coupl
deprotect
step
shown
scheme
cleavag
linear
hexapeptid
resin
use
mild
cleavag
reagent
hfip
result
sidechain
residu
protect
group
still
attach
solutionphas
macrocycl
done
use
hbtu
dipea
dmf
provid
protect
cyclohexapeptid
wollamid
b
obtain
remov
sidechain
protect
group
final
purif
use
flash
column
chromatographi
silica
gel
optim
studi
investig
effici
macrocycl
step
occur
six
peptid
bond
site
determin
macrocycl
linear
hexapeptid
precursor
termin
lleu
dleu
residu
provid
effici
macrocycl
without
detect
epimer
wollamid
b
highlight
scheme
first
fmoc
amino
acid
fmocasn
trt
oh
load
onto
resin
aid
dipea
dcm
hexapeptid
sequenc
correspond
wollamid
b
dorntrpleudleuvalasn
synthes
onresin
via
repeat
coupl
deprotect
step
shown
scheme
cleavag
linear
hexapeptid
resin
use
mild
cleavag
reagent
hfip
result
sidechain
residu
protect
group
still
attach
solutionphas
macrocycl
done
use
hbtu
dipea
dmf
provid
protect
cyclohexapeptid
wollamid
b
obtain
remov
sidechain
protect
group
final
purif
use
flash
column
chromatographi
silica
gel
optim
studi
investig
effici
macrocycl
step
occur
six
peptid
bond
site
determin
macrocycl
linear
hexapeptid
precursor
termin
lleu
dleu
residu
provid
effici
macrocycl
without
detect
epimer
group
report
antitubercular
antibacteri
activ
wollamid
b
desotamid
b
well
structur
analogu
thereof
optim
synthet
rout
access
compound
describ
previous
peptid
librari
screen
panel
gramposit
neg
bacteri
pathogen
discov
wollamid
b
positionii
lile
analogu
exhibit
promis
antibacteri
activ
mycobacterium
tuberculosi
mic
valu
favor
select
index
si
figur
cyclic
natur
wollamid
cyclohexapeptid
crucial
antibacteri
activ
correspond
linear
hexapeptid
precursor
show
activ
even
highest
concentr
test
residu
posit
ii
vi
found
major
impact
activ
select
henc
structureact
relationship
sar
studi
focu
optim
residu
highli
warrant
lewi
et
al
synthes
two
cyclic
hexapeptid
figur
order
probe
cell
permeabl
pk
properti
includ
oral
bioavail
demonstr
trinmethyl
peptid
experienc
increas
cell
permeabl
higher
plasma
protein
bind
decreas
clearanc
rate
compar
nonmethyl
variant
result
favor
bioavail
trinmethyl
cyclohexapeptid
cyclic
hexapeptid
cycloleudleuleuleudprotyr
cycloleunmedleunmeleuleudpronmetyr
synthes
use
tradit
spp
start
trityl
resin
preload
allyl
ester
fmoctyr
resinlink
via
tyr
sidechain
hydroxyl
group
scheme
resinlink
linear
hexapeptid
construct
use
sequenc
coupl
deprotect
step
allyl
ntermin
fmoc
group
remov
use
pd
pph
piperidinethf
respect
give
cycliz
onresin
use
hatuhobt
give
resinattach
cyclohexapeptid
cleavag
resin
use
tfa
provid
cyclohexapeptid
synthes
via
global
select
introduct
nmethyl
group
use
lio
bu
base
follow
mei
provid
resinattach
trimethyl
deriv
scheme
cleavag
resin
afford
altern
synthesi
also
investig
involv
stepwis
construct
trimethyl
linear
hexapeptid
use
tradit
spp
follow
cleavag
solutionphas
macrocycl
although
two
rout
synthesi
investig
first
rout
involv
global
nmethyl
resinbound
cyclohexapeptid
follow
cleavag
effici
provid
crude
higher
puriti
final
purif
figur
order
probe
cell
permeabl
pk
properti
includ
oral
bioavail
demonstr
trinmethyl
peptid
experienc
increas
cell
permeabl
higher
plasma
protein
bind
decreas
clearanc
rate
compar
nonmethyl
variant
result
favor
bioavail
trinmethyl
cyclohexapeptid
cyclic
hexapeptid
cycloleudleuleuleudprotyr
cycloleunmedleunmeleuleudpronmetyr
synthes
use
tradit
spp
start
trityl
resin
preload
allyl
ester
fmoctyr
resinlink
via
tyr
sidechain
hydroxyl
group
scheme
resinlink
linear
hexapeptid
construct
use
sequenc
coupl
deprotect
step
allyl
ntermin
fmoc
group
remov
use
pd
piperidinethf
respect
give
cycliz
onresin
use
hatuhobt
give
resinattach
cyclohexapeptid
cleavag
resin
use
tfa
provid
cyclohexapeptid
synthes
via
global
select
introduct
nmethyl
group
use
lio
bu
base
follow
mei
provid
resinattach
trimethyl
deriv
scheme
cleavag
resin
afford
altern
synthesi
also
investig
involv
stepwis
construct
trimethyl
linear
hexapeptid
use
tradit
spp
follow
cleavag
solutionphas
macrocycl
although
two
rout
synthesi
investig
first
rout
involv
global
nmethyl
resinbound
cyclohexapeptid
follow
cleavag
effici
provid
crude
higher
puriti
final
purif
wodtk
et
al
report
design
synthesi
cyclohexapeptid
analogu
contain
amino
acid
sequenc
inspir
aspglulyss
dek
motif
ntermin
telopeptid
type
collagen
suggest
dek
motif
adopt
conform
upon
dock
receptor
addit
conform
dek
motif
stabil
incorpor
cycliz
peptid
backbon
along
strateg
introduct
dpro
ly
residu
presenc
group
second
ly
could
applic
radiolabel
site
requir
incorpor
cyclohexapeptid
resist
bovin
trypsinmedi
degrad
min
time
correspond
linear
analogu
complet
digest
demonstr
cycliz
peptid
offer
enhanc
metabol
stabil
linear
counterpart
wodtk
et
al
report
design
synthesi
cyclohexapeptid
analogu
contain
amino
acid
sequenc
inspir
aspglulyss
dek
motif
ntermin
telopeptid
type
collagen
suggest
dek
motif
adopt
conform
upon
dock
receptor
addit
conform
dek
motif
stabil
incorpor
cycliz
peptid
backbon
along
strateg
introduct
dpro
ly
residu
presenc
group
second
ly
could
applic
radiolabel
site
requir
incorpor
cyclohexapeptid
resist
bovin
trypsinmedi
degrad
min
time
correspond
linear
analogu
complet
digest
demonstr
cycliz
peptid
offer
enhanc
metabol
stabil
linear
counterpart
synthesi
cyclohexapeptid
carri
accord
scheme
firstli
fmoclysoal
fmochnloal
load
onto
resin
attach
via
side
chain
thf
dipea
follow
cap
unreact
resin
site
methanol
subsequ
fmocamino
acid
ad
sequenc
use
standard
microwaveassist
spp
piperidin
hobt
dmf
fmoc
deprotect
step
fmocamino
acid
hbtu
dipea
nmp
coupl
step
resinbound
linear
hexapeptid
cycliz
onresin
use
hatu
dipea
dmf
deprotect
ctermin
allyl
ntermin
fmoc
group
pd
piperidin
dmf
respect
moieti
instal
onto
lysin
side
chain
use
chlorid
firstli
remov
dde
protect
group
hydrazin
cyclohexapeptid
cleav
resin
simultan
remov
sidechain
protect
group
use
cleavag
cocktail
solut
compris
tfatriethylsilan
te
give
good
yield
compound
synthes
cleav
cyclohexapeptid
resin
use
mild
acid
condit
tfatesdcm
give
sidechain
protect
group
attach
synthesi
cyclohexapeptid
carri
accord
scheme
firstli
fmoclysoal
fmochnloal
load
onto
resin
attach
via
side
chain
thf
dipea
follow
cap
unreact
resin
site
methanol
subsequ
fmocamino
acid
ad
sequenc
use
standard
microwaveassist
spp
piperidin
hobt
dmf
fmoc
deprotect
step
fmocamino
acid
hbtu
dipea
nmp
coupl
step
resinbound
linear
hexapeptid
cycliz
onresin
use
hatu
dipea
dmf
deprotect
ctermin
allyl
ntermin
fmoc
group
pd
pph
piperidin
dmf
respect
moieti
instal
onto
lysin
side
chain
use
chlorid
firstli
remov
dde
protect
group
hydrazin
cyclohexapeptid
cleav
resin
simultan
remov
sidechain
protect
group
use
cleavag
cocktail
solut
compris
tfatriethylsilan
te
give
good
yield
compound
synthes
cleav
cyclohexapeptid
resin
use
mild
acid
condit
tfatesdcm
give
sidechain
protect
group
attach
final
dessmartin
periodinan
oxid
follow
remov
sidechain
protect
group
provid
good
yield
jikyo
report
synthesi
cyclic
hexapeptid
use
onresin
headtotail
cycliz
strategi
trichloroacetimid
wang
resin
scheme
dser
side
chain
fmocdseroal
anchor
trichloroacetimid
wang
resin
use
dri
tfa
iter
coupl
deprotect
step
use
bophobtdipea
piperidinedmf
respect
five
cycl
construct
resinbound
linear
hexapeptid
intermedi
fmocbocoal
protect
group
intact
pd
nmm
use
anhydr
condit
complet
ctermin
oallyl
deprotect
addit
piperidin
dmf
remov
ntermin
fmoc
afford
anchor
linear
peptid
deprotect
cand
ntermin
onresin
cycliz
afford
achiev
pybophobtdipea
coupl
agent
cleavag
resin
use
tfa
result
cyclohexapeptid
yield
interestingli
onresin
cycliz
two
dpro
residu
chain
gave
highest
yield
cycliz
product
yield
jikyo
report
synthesi
cyclic
hexapeptid
use
onresin
headtotail
cycliz
strategi
trichloroacetimid
wang
resin
scheme
dser
side
chain
fmocdseroal
anchor
trichloroacetimid
wang
resin
use
bf
dri
tfa
iter
coupl
deprotect
step
use
bophobtdipea
piperidinedmf
respect
five
cycl
construct
resinbound
linear
hexapeptid
intermedi
fmocbocoal
protect
group
intact
pd
pph
chcl
acohnmethylmorpholin
nmm
use
anhydr
condit
complet
ctermin
oallyl
deprotect
addit
piperidin
dmf
remov
ntermin
fmoc
afford
anchor
linear
peptid
deprotect
cand
ntermin
onresin
cycliz
afford
achiev
pybophobtdipea
coupl
agent
cleavag
resin
use
tfa
result
cyclohexapeptid
yield
interestingli
onresin
cycliz
two
dpro
residu
chain
gave
highest
yield
cycliz
product
yield
cyclohexapeptid
figur
show
inhibitori
antibacteri
activ
methicillinresist
aureu
mrsa
mic
gml
mic
gml
mic
gml
aureu
mic
gml
increas
activ
compar
desotamid
b
therefor
suggest
replac
val
ile
improv
bioactiv
compound
show
loss
activ
mic
gml
suggest
dleu
necessari
antibacteri
activ
loss
activ
suggest
dorn
may
requir
antibacteri
activ
wollamid
b
howev
also
suggest
dorn
may
increas
cytotox
wollamid
b
show
higher
cytotox
assay
nearli
synthes
cyclopeptid
lack
cytotox
human
tumor
cell
except
wollamid
b
exhibit
cytotox
therefor
suggest
replac
val
ile
improv
bioactiv
compound
show
loss
activ
mic
suggest
dleu
necessari
antibacteri
activ
loss
activ
suggest
dorn
may
requir
antibacteri
activ
wollamid
b
howev
also
suggest
dorn
may
increas
cytotox
wollamid
b
show
higher
cytotox
assay
nearli
synthes
cyclopeptid
lack
cytotox
ic
human
tumor
cell
except
wollamid
b
exhibit
cytotox
ic
cyclohexapeptid
figur
show
inhibitori
antibacteri
activ
methicillinresist
aureu
mrsa
mic
gml
mic
gml
mic
gml
aureu
mic
gml
increas
activ
compar
desotamid
b
therefor
suggest
replac
val
ile
improv
bioactiv
compound
show
loss
activ
mic
gml
suggest
dleu
necessari
antibacteri
activ
loss
activ
suggest
dorn
may
requir
antibacteri
activ
wollamid
b
howev
also
suggest
dorn
may
increas
cytotox
wollamid
b
show
higher
cytotox
assay
nearli
synthes
cyclopeptid
lack
cytotox
human
tumor
cell
except
wollamid
b
exhibit
cytotox
fagundez
et
al
synthes
cyclohexapeptid
via
fmocspp
use
resin
follow
macrolactam
either
onresin
figur
solut
phase
cleavag
linear
peptid
precursor
resin
gener
method
onresin
cycliz
cyclohexapeptid
shown
scheme
synthesi
consist
peptid
sequenc
fagundez
et
al
synthes
cyclohexapeptid
via
fmocspp
use
resin
follow
macrolactam
either
onresin
figur
solut
phase
cleavag
linear
peptid
precursor
resin
gener
method
onresin
cycliz
cyclohexapeptid
shown
scheme
synthesi
consist
peptid
sequenc
synthes
resin
similar
fashion
discuss
cleav
undergo
macrocycl
solut
phase
compound
produc
onresin
cycliz
allow
new
deriv
synthes
result
presenc
free
carboxyl
acid
solutionphas
cycliz
result
abil
produc
divers
cyclic
peptid
howev
onresin
rout
conveni
larger
amount
product
higher
yield
accept
puriti
could
produc
howev
onresin
rout
conveni
larger
amount
product
higher
yield
accept
puriti
could
produc
activ
chloroquineresist
strain
p
falciparum
synthes
cyclopeptid
determin
two
cyclopentapeptid
also
synthes
compar
cyclic
hexapeptid
found
less
activ
six
synthes
cyclic
hexapeptid
exhibit
submicromolar
activ
p
falciparum
hexapeptid
exhibit
free
carboxyl
group
glu
permit
product
deriv
product
solubl
salt
cyclic
hexapeptid
cycloci
trt
glythr
bu
glyci
trt
gli
determin
activ
well
select
p
falciparum
nm
suggest
biolog
activ
affect
substitut
larger
hydrophob
amino
acid
phe
met
ile
contain
gli
well
retent
one
thr
two
cy
acid
solutionphas
cycliz
result
abil
produc
divers
cyclic
peptid
howev
onresin
rout
conveni
larger
amount
product
higher
yield
accept
puriti
could
produc
activ
chloroquineresist
strain
p
falciparum
synthes
cyclopeptid
determin
two
cyclopentapeptid
also
synthes
compar
cyclic
hexapeptid
found
less
activ
six
synthes
cyclic
hexapeptid
exhibit
submicromolar
activ
p
falciparum
hexapeptid
exhibit
free
carboxyl
group
glu
permit
product
deriv
product
solubl
salt
cyclic
hexapeptid
cycloci
trt
glythr
bu
glyci
trt
gli
determin
activ
well
select
p
falciparum
nm
suggest
biolog
activ
affect
substitut
larger
hydrophob
amino
acid
phe
met
ile
contain
gli
well
retent
one
thr
two
cy
activ
chloroquineresist
strain
p
falciparum
synthes
cyclopeptid
determin
two
cyclopentapeptid
also
synthes
compar
cyclic
hexapeptid
found
less
activ
six
synthes
cyclic
hexapeptid
exhibit
submicromolar
activ
p
falciparum
hexapeptid
exhibit
free
carboxyl
group
glu
permit
product
deriv
product
solubl
salt
cyclic
hexapeptid
cycloci
trt
glythr
bu
glyci
trt
gli
determin
activ
well
select
p
falciparum
ec
nm
suggest
biolog
activ
affect
substitut
larger
hydrophob
amino
acid
phe
met
ile
contain
gli
well
retent
one
thr
two
cy
togeth
onresin
headtotail
cycliz
strategi
peptid
stay
anchor
resin
throughout
final
cycliz
step
wherea
classic
method
report
previou
studi
cleavag
onresin
linear
precursor
occur
cycliz
solut
phase
suggest
onresin
headtotail
cycliz
strategi
could
improv
process
synthes
cyclic
peptid
well
reduc
quantiti
product
lost
synthesi
conclus
cyclohexapeptid
repres
import
class
natur
product
medicin
molecul
compar
linear
hexapeptid
counterpart
macrocycl
hexapeptid
often
possess
improv
cell
permeabl
higher
metabol
stabil
enhanc
bioavail
result
cyclic
natur
incorpor
unnatur
amino
acid
spp
enabl
rapid
effici
synthesi
hexapeptid
peptidomimet
librari
subsequ
biolog
evalu
highthroughput
screen
review
summar
recent
method
use
success
construct
cyclohexapeptid
use
spp
follow
onresin
solutionphas
cycliz
also
highlight
recent
advanc
solidphas
hexapeptid
synthesi
applic
rang
natur
product
total
synthesi
synthet
methodolog
develop
medicin
activ
drug
develop
analys
conform
physiochem
properti
headtotail
cycliz
linear
peptid
accomplish
either
onresin
solutionphas
macrolactam
releas
resin
advantag
onresin
cycliz
format
linear
andor
cyclic
oligomer
side
product
minim
addit
cycliz
onresin
shorten
synthet
rout
minim
purif
step
although
reaction
progress
challeng
monitor
case
solutionphas
cycliz
perform
reaction
dilut
condit
mm
favor
cycliz
dimeroligom
format
exampl
ad
linear
peptid
precursor
dropwis
fashion
maintain
high
dilut
use
success
util
turninduc
pseudoprolin
residu
greatli
enhanc
cycliz
rate
although
requir
deprotect
post
cycliz
addit
reaction
step
hand
epimer
ctermin
amino
acid
cycliz
attenu
employ
effici
coupl
reagent
azabenzotriazol
class
furthermor
epimer
complet
avoid
choos
cycliz
nonepimeriz
residu
ctermin
gli
applic
employ
method
onacyl
migrat
cyclodepsipeptid
precursor
among
variou
solid
support
resin
remain
one
popular
resin
spp
mild
acidolyt
cleavag
condit
well
steric
effect
prevent
diketopiperazin
format
author
declar
conflict
interest
follow
abbrevi
use
manuscript
